Cadence Pharmaceuticals (CADX) said on Friday that in a pivotal late-stage trial, its IV-administered Acetavance for pain and fever didn't meet a primary endpoint.

Shares of the San Diego-based biopharmaceutical company plunged $8.43, or 60.3%, to $5.59 after Cadence said the drug didn't demonstrate a statistically significant reduction in patients' pain over 48 hours compared to the placebo after abdominal gynecologic surgery.

Acetavance did reduce fever in a separate, smaller study, and was safe and well-tolerated in both studies, according to the company.

The drug was successful in prior late-stage studies on postoperative pain, and is currently sold in Europe by Bristol-Myers Squibb ( BMY). Cadence said in a conference call that it will meet with the FDA and discuss the study and results development program.

Aside from Acetavance, Cadence is also developing a drug for the prevention of catheter-related infections.

More from Stocks

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes